327 filings
Page 6 of 17
8-K
d03o7
9 Oct 18
Announce New License Agreement
7:13am
8-K
v6agw72fvj
24 Sep 18
Departure of Directors or Certain Officers
4:24pm
8-K
a7uopee8xp9024vyt
8 Aug 18
Ziopharm Oncology Reports Second Quarter 2018 Financial
4:07pm
8-K
4lo5eh79asvzbhog
27 Jul 18
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
7:30am
8-K
3ktnmcwb0 tc
18 Jun 18
Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy
7:40am
8-K
x3hehm
10 May 18
Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update
4:56pm
8-K
bh9ich
13 Mar 18
Departure of Directors or Certain Officers
12:00am
8-K
5s6zx0ivf2kz8
1 Mar 18
Ziopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
12:00am
8-K
bn8oy43dwfx
22 Feb 18
Departure of Directors or Certain Officers
12:00am
8-K
hw2fr15 rvi9s38apkr
6 Feb 18
Other Events
12:00am
8-K
s3quz0ictx ds
5 Feb 18
Departure of Directors or Certain Officers
12:00am
8-K
5v9ab8g
11 Jan 18
Regulation FD Disclosure
12:00am
8-K
d4eaprlv 4c18y8
9 Jan 18
Ziopharm Oncology Provides Update on Standout Technologies
12:00am
8-K
stcy4h
6 Nov 17
ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities
12:00am
8-K
n5xk0ily0y0uxi
28 Sep 17
ZIOPHARM Oncology Appoints David Mauney, M.D., as EVP and Chief Business
12:00am
8-K
7lhojfy66fu
31 Jul 17
Results of Operations and Financial Condition
12:00am
8-K
y8maslwy
15 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
atmbjulp3u74 m4q
5 Jun 17
ZIOPHARM Oncology Announces Positive Updated Results ofAd-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting
12:00am
8-K
y406f8 0g2fx27pm
12 May 17
Ziopharm Oncology Announces Pricing of $50 Millionfollow-on Offering of Common Stock
12:00am
8-K
3yl1t7x620qmrb
2 May 17
ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-SpecificCAR-T Cell
12:00am